SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is drawing heavy social media attention as investors anticipate imminent clinical milestones from the Phase 3 REGAL trial for its AML treatment. The community is actively debating the stock's high short interest and potential for a significant squeeze, while others remain skeptical about trial design and the company's long-term commercial outlook.

Litecoin is a decentralized, peer-to-peer digital currency designed to enable instant, near-zero cost payments to individuals and merchants worldwide. As an open-source global payment network that functions independently of central banks or intermediaries, its main value proposition lies in providing a scarce digital asset with a fixed maximum supply of 84 million tokens.  The network operates using a Proof of Work mechanism where computers solve complex puzzles to confirm transactions and secure the blockchain. It is distinguished by a block generation time of 2.5 minutes, which allows for faster transaction confirmations and a higher total throughput than earlier protocols. Key technical features include the Scrypt hashing algorithm, which promotes wider network participation, and MimbleWimble Extension Blocks, which improve user privacy by allowing transaction details to be hidden.  The LTC token is used for settling global payments, executing microtransactions through smaller units called litoshis, and diversifying digital portfolios with a highly liquid asset. New tokens are issued to miners as rewards for verifying blocks, though these rewards undergo a halving event approximately every four years to strictly control inflation. This process ensures the ledger maintains immutability, meaning records cannot be changed once they are saved to the global network.  Created by former Google engineer Charlie Lee, the project is supported by the Litecoin Foundation, a non-profit organization dedicated to ecosystem adoption. Unlike many venture-backed projects, it is maintained by a decentralized community of independent developers and a global network of miners. The project has seen recent institutional adoption, with entities like Lite Strategy and Luxxfolio Holdings adding significant amounts of LTC to their corporate treasuries as of late 2025.

Litecoin

Litecoin is experiencing intense community focus as market participants debate its long-term potential following a move to multi-year lows, with many comparing its transparent, capped supply to other assets facing volatility. Investors are actively discussing potential accumulation zones and historical patterns, hoping that increasing transaction activity and network development will trigger a significant recovery.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is seeing significant community debate as investors weigh strong enterprise fundamentals and institutional buyback activity against persistent volatility in the software sector. The stock is being closely monitored for a potential rotation out of hardware-focused AI plays, with many participants looking for a decisive break above key technical resistance levels ahead of upcoming earnings.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is trending due to volatile price action and intense community speculation regarding potential short squeezes and upcoming token movements. While some investors remain optimistic about a sustained rally, others are actively debating whether the current activity is a recurring pump-and-dump cycle.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is experiencing heightened community interest as investors weigh its pivot toward a potential eBay acquisition against recent optimistic forward EBITDA guidance. The stock remains a focal point for retail discussions, with many participants comparing current sentiment and price action to previous meme stock rallies while debating the company's long-term transformation strategy.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCellera Biologics is experiencing a period of heightened interest and intense debate, driven by a recent T-cell engager partnership with Jazz Pharmaceuticals and growing anticipation for Phase 2 clinical trial results. While the community is actively debating the stock's long-term potential as an AI-driven drug discovery play versus its history of price underperformance, significant discussion centers on high short interest, institutional accumulation, and the potential for a technical breakout on heavy volume.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is experiencing significant momentum driven by optimistic FDA briefing documents regarding its influenza vaccine and a strategic leadership overhaul aimed at supporting major commercial launches in 2027 and 2028. The community is actively debating the firm's pivot toward an oncology-focused pipeline and its potential as a long-term play, while keeping a close watch on high short interest and the possibility of a squeeze.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as community members speculate on a potential buyout following recent high trading volume and price volatility. Long-term investors remain divided, with some pointing to the strong commercial potential of the company's rare disease pipeline, while others express frustration over stagnant price performance and a perceived lack of urgency from leadership.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Digital is trending as investors weigh an $810 million notes offering against its long-term AI data center infrastructure deals with major hyperscalers like AWS. Community sentiment is deeply polarized, with bulls viewing the infrastructure buildout as a multi-year growth catalyst while bears point to market volatility, dilution concerns, and ongoing sector-wide price swings.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending as investors weigh anticipation for potential government-backed drone equity investments and contract announcements against frustration over insider selling and a lack of confirmed, scalable revenue. The community is actively debating the company's long-term defense market position versus management's ability to execute, with sentiment oscillating between bullish technical setups and skepticism regarding the pace of product deployment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IVVD Stock Tanks 19% Today – But This Analyst Believes It Has A Potential Upside Of Over 730%

Equity

Invivyd posted a first-quarter revenue of $13.7 million, sharply below Wall Street’s estimates of around $18 million, according to Fiscal.ai data.

Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates

Invivyd, Inc. (IVVD) delivered earnings and revenue surprises of -62.50% and -25.30%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates

Upstream Bio, Inc. (UPB) delivered earnings and revenue surprises of +5.96% and +102.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

TELA Bio, Inc. (TELA) Reports Q1 Loss, Beats Revenue Estimates

TELA Bio (TELA) delivered earnings and revenue surprises of -50.00% and +3.02%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Invivyd (IVVD) Expected to Announce Quarterly Earnings on Thursday

Invivyd (NASDAQ:IVVD) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...

Invivyd, Inc. (NASDAQ:IVVD) Receives Consensus Rating of "Hold" from Analysts

Shares of Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) have been given a consensus recommendation of "Hold" by the six research firms that are covering the company, MarketBeat reports. One equities...

Invivyd Updates VYD2311 REVOLUTION Trials, Modestly Upsizes Study, Unveils Measles mAb VMS-063

Invivyd (NASDAQ:IVVD) provided updates on its REVOLUTION program for COVID-19 monoclonal antibody candidate VYD2311 and announced the discovery and early development work for a measles monoclonal antibody candidate, VMS-063, during a conference call led by board chairman Marc Elia alongside Chief Sc...

Invivyd Stock Surges As FDA Alignment Boosts COVID-19 Program

Invivyd expands VYD2311 COVID study, delays timeline to Q3 2026, and advances measles antibody VMS063 toward clinical development.read more...

Invivyd, Inc. (NASDAQ:IVVD) Given Consensus Rating of "Hold" by Analysts

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) has received an average rating of "Hold" from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and t...

FY2027 Earnings Estimate for Invivyd Issued By HC Wainwright

Invivyd, Inc. (NASDAQ:IVVD - Free Report) - HC Wainwright reduced their FY2027 EPS estimates for shares of Invivyd in a research report issued to clients and investors on Tuesday, March 10th. HC...

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in New Haven, CT.

Invivyd Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.11	--	--	N/A
Q1 '26	-$0.07	-$0.13	-77.27%	MISSED
Q4 '25	-$0.08	$0.02	124.01%	BEAT
Q3 '25	-$0.08	-$0.06	25.00%	BEAT
Q2 '25	-$0.02	-$0.12	-424.77%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

IVVDInvivyd Inc

Upcoming Earnings: Q2 '26

Historical Earnings

Latest IVVD News